DE69230041T2 - Muramylverbindungen zur behandlung von septischem schock - Google Patents

Muramylverbindungen zur behandlung von septischem schock

Info

Publication number
DE69230041T2
DE69230041T2 DE69230041T DE69230041T DE69230041T2 DE 69230041 T2 DE69230041 T2 DE 69230041T2 DE 69230041 T DE69230041 T DE 69230041T DE 69230041 T DE69230041 T DE 69230041T DE 69230041 T2 DE69230041 T2 DE 69230041T2
Authority
DE
Germany
Prior art keywords
muramyl
pct
acetyl
date
septic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69230041T
Other languages
English (en)
Other versions
DE69230041D1 (de
Inventor
Roger Aston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Peptech UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919124500A external-priority patent/GB9124500D0/en
Priority claimed from GB929210013A external-priority patent/GB9210013D0/en
Application filed by Peptech UK Ltd filed Critical Peptech UK Ltd
Application granted granted Critical
Publication of DE69230041D1 publication Critical patent/DE69230041D1/de
Publication of DE69230041T2 publication Critical patent/DE69230041T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69230041T 1991-11-19 1992-11-19 Muramylverbindungen zur behandlung von septischem schock Expired - Lifetime DE69230041T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919124500A GB9124500D0 (en) 1991-11-19 1991-11-19 Compounds for medicinal use
GB929210013A GB9210013D0 (en) 1992-05-08 1992-05-08 Compounds for medicinal use
PCT/GB1992/002137 WO1993010148A1 (en) 1991-11-19 1992-11-19 Muramyl compounds for treatment of septic shock

Publications (2)

Publication Number Publication Date
DE69230041D1 DE69230041D1 (de) 1999-10-28
DE69230041T2 true DE69230041T2 (de) 2000-01-05

Family

ID=26299886

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230041T Expired - Lifetime DE69230041T2 (de) 1991-11-19 1992-11-19 Muramylverbindungen zur behandlung von septischem schock

Country Status (9)

Country Link
US (1) US5506204A (de)
EP (1) EP0615522B1 (de)
JP (1) JP3628689B2 (de)
AT (1) ATE184883T1 (de)
AU (1) AU666890B2 (de)
CA (1) CA2123912C (de)
DE (1) DE69230041T2 (de)
RU (1) RU2139086C1 (de)
WO (1) WO1993010148A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) * 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
WO1997005889A1 (en) * 1995-08-03 1997-02-20 Slesarev Vladimir I Non-specific vaccination by d-amino-acid containing compounds
US6200955B1 (en) * 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5834435A (en) * 1996-11-27 1998-11-10 Slesarev; Vladimir I. Inhibition of TNF-α pleiotropic and cytotoxic effects
EP1053001B1 (de) 1998-02-13 2010-12-15 Amylin Pharmaceuticals, Inc. Neue verbindungen mit gemischter amylin aktivität
IL152157A0 (en) 2000-04-18 2003-05-29 Lilly Co Eli Process for preparing lipid ii
WO2001079268A2 (en) * 2000-04-18 2001-10-25 Eli Lilly And Company A glycopeptide and preparation thereof
US7112564B2 (en) * 2003-04-09 2006-09-26 Zylacta Corporation Biodegradable glucosaminemuramyl peptides for apoptosis modulation
WO2005007676A2 (en) * 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
ES2856081T3 (es) 2007-04-16 2021-09-27 Occlutech Holding Ag Oclusor para la oclusión de una orejuela auricular y procedimiento de producción del mismo
US8188058B2 (en) 2007-04-19 2012-05-29 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
US9562066B2 (en) 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
EA025690B1 (ru) * 2014-07-15 2017-01-30 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Ранозаживляющее средство, обладающее иммуностимулирующим и антиоксидантным эффектами
RU2584089C1 (ru) * 2015-06-15 2016-05-20 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Медицинский Университет Имени В.И. Разумовского" Министерства Здравоохранения Российской Федерации Способ снижения летального эффекта бактериального липополисахарида in vitro
JP2024511067A (ja) 2021-03-19 2024-03-12 トレインド セラピューティクス ディスカバリー,インコーポレーテッド 訓練された免疫を調節するための化合物およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU727647A1 (ru) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
JPS5543030A (en) * 1978-09-21 1980-03-26 Dai Ichi Seiyaku Co Ltd Prophylactic and remedy for microbial infection disease
FR2449697A1 (fr) * 1979-02-20 1980-09-19 Anvar Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
JP2545279B2 (ja) * 1987-09-02 1996-10-16 第一製薬株式会社 血小板減少予防及び治療剤

Also Published As

Publication number Publication date
JPH07508497A (ja) 1995-09-21
ATE184883T1 (de) 1999-10-15
WO1993010148A1 (en) 1993-05-27
CA2123912C (en) 2007-04-17
EP0615522A1 (de) 1994-09-21
RU2139086C1 (ru) 1999-10-10
EP0615522B1 (de) 1999-09-22
AU2949292A (en) 1993-06-15
JP3628689B2 (ja) 2005-03-16
CA2123912A1 (en) 1993-05-27
RU94027574A (ru) 1996-07-20
DE69230041D1 (de) 1999-10-28
US5506204A (en) 1996-04-09
AU666890B2 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
DE69230041T2 (de) Muramylverbindungen zur behandlung von septischem schock
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69421912T2 (de) Methode zur behandlung von wasser
HK1016213A1 (en) Il-6 activity inhibitor
GB9323165D0 (en) Compounds
PT988301E (pt) Acetais ciclicos de imidazolilo
DE69527765D1 (de) Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen
DE69331665D1 (de) Methode zur behandlung von nukleinsäureproben
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
DE69203828D1 (de) Verfahren zur behandlung von produkten roter blutkörperchen zur langzeitlagerung frei von mikroorganismen.
DE59201870D1 (de) Verfahren zur Herstellung von substituierten Malonesteraniliden und Malonsäure-monoaniliden.
GB9506684D0 (en) Control of pod dehiscence
DE69927831D1 (de) Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69129953D1 (de) Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus
ATE198751T1 (de) Azoderivate von 5-aminosalicylsäure zur behandlung von enzündlichen darmerkrankungen
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
DE69300667D1 (de) Verfahren zur thermischen Behandlung von verbrauchten Auskleidungen aus elektrolytischen Hall-Heroult Zellen.
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69634411D1 (de) Methode zur kontrolle der züchtung von milchsäurebakterien
FR2672895B1 (fr) Procede de purification d'une proteine fortement glycosylee.
FR2674844B1 (fr) Procede et installation de traitement d'epuration de lisiers d'animaux.
DE69105823D1 (de) Verfahren zur Behandlung von Metallmatrixverbundwerkstoffen.
DE68907386D1 (de) Verwendung von phytinsaeure oder deren salzen zur verhinderung oder behandlung von lebererkrankungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PEPTECH LTD., MACQUARIE PARK, NEUSUEDWALES, AU